1.
Bioorg Med Chem Lett
; 14(21): 5389-94, 2004 Nov 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15454232
RESUMO
SAR studies led to the identification of 4-(3-benzoylamino-6-methyl-anilino)quinazolines as potent and selective inhibitors of p38 MAP kinase. Further optimisation led to the identification of a series of 4-(3-benzoylamino-6-methyl-anilino)pyrimidines as potent inhibitors of the p38 MAP kinase signalling pathway in vitro and in vivo.